Navigation Links
Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
Date:11/6/2007

eveloping alagebrium, a proposed breaker of AGEs for the treatment of diastolic heart failure. This disease represents a rapidly growing market of unmet medical need, particularly common among diabetic patients. Alagebrium has demonstrated relevant clinical activity in two Phase 2 clinical trials in heart failure, as well as in animal models of heart failure and nephropathy, among others. Alagebrium has been tested in approximately 1,000 patients in multiple Phase 1 and Phase 2 clinical trials, allowing Synvista Therapeutics to assemble a sizeable human safety database. For more information, please visit the Company's website at http://www.synvista.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the events described in this press release, future clinical development of Synvista Therapeutics' product candidates, and other risks identified in Synvista Therapeutics' filings with the Securities and Exchange Commission. Further information on risks faced by Synvista are detailed under the caption "Risk Factors" in Synvista Therapeutics' Annual Report on Form 10-K for the year ended December 31, 2006. These filings are available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Synvista Therapeutics undertakes no obligation to publicly release the result of any revision to these forward- looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Synvista Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
2. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
3. Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)...  Aethlon Medical, Inc. (OTCQB:AEMD), announced today that it ... $3.3 million at a price of $0.30 per unit. ... investor. Each unit consists of one common share and ... Each whole warrant entitles the holder to acquire one ... period of five years from closing.  ...
(Date:11/26/2014)... 26, 2014 Lexicon Pharmaceuticals, Inc. (Nasdaq: ... of previously announced concurrent financing transactions resulting in ... estimated offering expenses, Lexicon anticipates net proceeds of ... consisted of: , a public offering ... a registration statement that has been declared effective ...
(Date:11/26/2014)... , November 26, 2014 Investor-Edge has ... VVUS ), Horizon Pharma PLC (NASDAQ: HZNP ... Johnson (NYSE: JNJ ), and Theravance Inc. (NASDAQ: ... can be accessed at: http://investor-edge.com/register . On ... up 0.07%, the Dow Jones Industrial Average edged 0.02% lower, ...
Breaking Medicine Technology:Aethlon Medical Announces $3.3 Million Equity Investment 2Aethlon Medical Announces $3.3 Million Equity Investment 3Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5
... , Increased vaccination ... gaps remain, others must join effort , DAVOS, Switzerland ... announced today that their foundation will commit $10 billion ... deliver vaccines for the world,s poorest countries. , (Photo: ...
... , , REDWOOD CITY, Calif. ... today announced financial results for its fiscal second quarter and six months ... call at 4:30 p.m. Eastern Time to discuss the financial ... quarter, as we continued to transition the sales model for our cardiac ...
Cached Medicine Technology:Bill and Melinda Gates Pledge $10 Billion in Call for Decade of Vaccines 2Bill and Melinda Gates Pledge $10 Billion in Call for Decade of Vaccines 3Bill and Melinda Gates Pledge $10 Billion in Call for Decade of Vaccines 4Bill and Melinda Gates Pledge $10 Billion in Call for Decade of Vaccines 5Bill and Melinda Gates Pledge $10 Billion in Call for Decade of Vaccines 6Cardica Announces Fiscal 2010 Second Quarter Financial Results 2Cardica Announces Fiscal 2010 Second Quarter Financial Results 3Cardica Announces Fiscal 2010 Second Quarter Financial Results 4Cardica Announces Fiscal 2010 Second Quarter Financial Results 5Cardica Announces Fiscal 2010 Second Quarter Financial Results 6Cardica Announces Fiscal 2010 Second Quarter Financial Results 7Cardica Announces Fiscal 2010 Second Quarter Financial Results 8Cardica Announces Fiscal 2010 Second Quarter Financial Results 9
(Date:11/28/2014)... Dr. Diane Walder, one of South Florida’s top cosmetic ... called Ultrashape that is designed to help her patients reduce ... weeks. Ultrashape has been praised by patients as being permanent, ... to other types of external fat reduction. , “If you ... , According to Dr. Walder, Ultrashape works by targeting ...
(Date:11/28/2014)... The Alternative Health Therapies ... past five years. The industry has been buoyed ... are either alternative to conventional Western medicine or ... analyst David Whytcross, “industry revenue has been further ... health insurance membership.” Meanwhile, improving economic conditions following ...
(Date:11/28/2014)... Celebration can quickly turn to tragedy if popular turkey ... Over the last decade, more than 141 serious fires ... turkey fryers, according to the U.S. Consumer Product Safety ... who tried to deep fry the turkey indoors, which ... Arthur Sanford, a burn surgeon at Loyola University Health ...
(Date:11/28/2014)... Not only is the Éminence Organic Skin Care team ... other cancer-causing agents, but they are also proud to ... that help in the fight against breast cancer. This ... record-breaking contribution of $30,000 through participation in the CIBC ... Rose Whip Moisturizer and the company’s corporate donation. , ...
(Date:11/28/2014)... 28, 2014 Earlier in the ... the hugely popular, 2014 MTV Video Music Awards ... launched ground-breaking celebrity centered television advertisements directed at ... figures were estimated by Entertainment Weekly ... the spotlight on celebrities photographed by paparazzi smoking. ...
Breaking Medicine News(10 mins):Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 3Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Turkey Fryer Mishaps Can Cause Serious Burns 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 2Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 4Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 5
... - Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com Mellow ... that its clinical trial is currently being processed. The company ... days). The company expects the manufacturing license will be released ... to as "swine flu" early on) is a new influenza ...
... Hospitals, Physicians Work Together to Cut Costs, Improve ... 18 Twelve New Jersey hospitals and their participating physicians have ... incentive method that aims to reduce healthcare costs while improving quality ... could serve as a basis to overhaul government payment for Medicare ...
... , , LOS ANGELES, Aug. ... El Cancer (PADRES), a non-profit organization committed to improving the quality ... celebrate its ninth annual fund-raising gala, " EL SUENO DE ESPERANZA ... pay tribute to PADRES, extraordinary children and families, while at the ...
... speed, report shows , TUESDAY, Aug. 18 (HealthDay News) ... viral infection norovirus from a novel source: a tobacco ... tobacco plant using a bioengineered plant virus. , This ... ways to bring vaccines to the public quickly, especially ...
... PHILADELPHIA, Aug. 18 EwingCole, a nationally ... more than 320 professionals, today announced that it will ... Philadelphia, a 40-person firm with a robust portfolio of ... to take effect by September 1, 2009, will create ...
... , , , AUSTIN, ... a full-service pet travel company providing worldwide door-to-door pet trans ... pet health resource, P e tMD , to ... , The strategic affiliation will allow guests of PetMD to ...
Cached Medicine News:Health News:Hard To Treat Diseases (HTDS.PK) H1N1 Swine Flu Clinical Trial 2Health News:Hard To Treat Diseases (HTDS.PK) H1N1 Swine Flu Clinical Trial 3Health News:Medicare Picks N.J. to Test Innovative Incentive System 2Health News:Medicare Picks N.J. to Test Innovative Incentive System 3Health News:Medicare Picks N.J. to Test Innovative Incentive System 4Health News:Eva Longoria Parker and George Lopez Return to Host 9th Annual PADRES' Contra El Cancer's 'EL SUENO DE ESPERANZA' Gala 2Health News:Eva Longoria Parker and George Lopez Return to Host 9th Annual PADRES' Contra El Cancer's 'EL SUENO DE ESPERANZA' Gala 3Health News:Eva Longoria Parker and George Lopez Return to Host 9th Annual PADRES' Contra El Cancer's 'EL SUENO DE ESPERANZA' Gala 4Health News:'Cruise Ship Virus' Vaccine Stems From Tobacco 2Health News:EwingCole, RDLA Join Together, Creating Architecture/Engineering Firm With Largest Healthcare Focus in the Delaware Valley 2Health News:EwingCole, RDLA Join Together, Creating Architecture/Engineering Firm With Largest Healthcare Focus in the Delaware Valley 3Health News:PetRelocation.com and PetMD.com Launch Co-Branded Pet Travel and Pet Health Resources 2Health News:PetRelocation.com and PetMD.com Launch Co-Branded Pet Travel and Pet Health Resources 3
... The ABI PRISM 310 Genetic Analyzer ... for a wide range of sequencing and ... for academic and forensic labs who incorporate ... Genetic Analyzer -- the ideal alternative to ...
... Conforming to U.S. and international engineering ... TC-100 Screw and Plating System* provides ... ease of use for open reduction ... the TC-100 system works well beyond ...
Comprehensive range of integrated implants and instruments including - Basic, Small, Mini, Pelvic and Foot Sets....
Comprehensive range of integrated implants and instruments including - Basic, Small, Mini, Pelvic and Foot Sets....
Medicine Products: